Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. D-propoxyphene Napsylate
2. Dextropropoxyphene Napsylate
1. 17140-78-2
2. Propoxyphene Napsylate Anhydrous
3. 5o7iw35n3c
4. Darvon N
5. [(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] Propanoate;naphthalene-2-sulfonic Acid
6. Propoxyphene-n
7. (+)- Propoxyphene Napsylate
8. Propoxyphene 2-naphthalenesulfonate
9. Einecs 241-205-7
10. Unii-5o7iw35n3c
11. 2-butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, Propionate, 2-naphthalenesulfonate
12. Propoxyphene Napsylate ,(s)
13. 2-naphthalenesulfonic Acid, Compd. With (s-(r*,s*))-3-(dimethylamino)-2-methyl-1-phenyl-1-(phenylmethyl)p- Ropyl Propanoate (1:1)
14. Schembl9297768
15. Dtxsid80937986
16. Propoxyphene Napsylate, Anhydrous
17. 2-naphthalenesulfonic Acid, Compd. With (+)-alpha-(2-dimethylamino)-1-methylethyl-alpha-phenylphenethyl Propionate (1:1)
18. Benzeneethanol, Alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, Propanoate (ester), (1s,2r)-, 2-naphthalenesulfonate (salt)
19. Benzeneethanol, Alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, Propanoate (ester), (s-(r*,s*))-, 2-naphthalenesulfonate (salt)
20. Naphthalene-2-sulphonic Acid, Compound With (s-(r*,s*))-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl Propionate (1:1)
21. Q27262632
22. (2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl Propionate Naphthalene-2-sulfonate
Molecular Weight | 547.7 g/mol |
---|---|
Molecular Formula | C32H37NO5S |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 10 |
Exact Mass | 547.23924445 g/mol |
Monoisotopic Mass | 547.23924445 g/mol |
Topological Polar Surface Area | 92.3 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 688 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Related Excipient Companies
Excipients by Applications
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
14
PharmaCompass offers a list of Propoxyphene Napsylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Propoxyphene Napsylate manufacturer or Propoxyphene Napsylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Propoxyphene Napsylate manufacturer or Propoxyphene Napsylate supplier.
PharmaCompass also assists you with knowing the Propoxyphene Napsylate API Price utilized in the formulation of products. Propoxyphene Napsylate API Price is not always fixed or binding as the Propoxyphene Napsylate Price is obtained through a variety of data sources. The Propoxyphene Napsylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS, including repackagers and relabelers. The FDA regulates LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS supplier is an individual or a company that provides LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS active pharmaceutical ingredient (API) or LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS finished formulations upon request. The LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS suppliers may include LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS API manufacturers, exporters, distributors and traders.
click here to find a list of LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS DMF (Drug Master File) is a document detailing the whole manufacturing process of LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS active pharmaceutical ingredient (API) in detail. Different forms of LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS DMFs exist exist since differing nations have different regulations, such as LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS DMF submitted to regulatory agencies in the US is known as a USDMF. LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS USDMF includes data on LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS suppliers with USDMF on PharmaCompass.
LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS GMP manufacturer or LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS GMP API supplier for your needs.
A LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS CoA (Certificate of Analysis) is a formal document that attests to LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS's compliance with LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS specifications and serves as a tool for batch-level quality control.
LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS CoA mostly includes findings from lab analyses of a specific batch. For each LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS may be tested according to a variety of international standards, such as European Pharmacopoeia (LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS EP), LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS USP).